Description
Retatrutide (LY3437943) is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It represents one of the most advanced compounds in metabolic and cardiometabolic research, with Phase 2 clinical trial data published in the New England Journal of Medicine (2023) showing significant effects on body weight and metabolic markers.
RESEARCH APPLICATIONS
Retatrutide is being actively studied in the context of metabolic regulation, adipose tissue signaling, insulin sensitivity, and cardiovascular risk markers. Its triple agonist mechanism distinguishes it from GLP-1 single agonists and dual GLP-1/GIP agonists in preclinical and clinical models.
PRODUCT SPECIFICATIONS
– Form: Lyophilized powder
– Peptide content: 10mg per vial
– Purity: ≥98% (HPLC verified)
– Testing: Independent third-party mass spectrometry
– Storage: -20°C long-term / 4°C short-term
– Reconstitution: Bacteriostatic water recommended
For research use only. Not for human consumption.